Pricing

Bio Path Holdings Inc (BPTH)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Peter H. Nielsen
Employees:
10
4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, TX, 77401
(832) 742-1357
    Formally known as:
  • Bio-Path Holdings Inc
  • BIO-PATH HOLDINGS INC (DE) COMMON
Stock Split History
DateRatio
2018-02-09 1:10
2019-01-18 1:20
2024-02-23 1:20
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company develops products based on DNAbilize, a drug delivery and antisense technology.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available